Evaluating the addition of Venetoclax for treating chronic lymphocytic leukemia.
Benefit of Venetoclax Addition ("Benefit VA") in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
This study is looking at whether adding Venetoclax to the treatment for people with chronic lymphocytic leukemia who are already doing well on another medication can make the treatment work better and cause fewer side effects, all while helping improve your quality of life.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Kansas City VA Medical Center NIH-funded |
| Lab location | 1 site (Kansas City, United States) |
| Project ID | NIH-10801637 on NIH RePORTER |
What this research studies
This research investigates the effects of adding Venetoclax to the treatment regimen of patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who are already responding to Bruton’s tyrosine kinase inhibitors (BTKi). The study aims to determine if this combination therapy can enhance treatment effectiveness while reducing long-term side effects. Patients will receive both medications for one year, after which both will be discontinued to assess the depth of response and overall patient experience. The focus is on improving quality of life and minimizing toxicities associated with ongoing treatment.
Who could benefit from this research
Good fit: Ideal candidates for this research are veterans diagnosed with chronic lymphocytic leukemia/small lymphocytic lymphoma who are currently being treated with BTKi and are responding positively.
Not a fit: Patients who are not veterans or those who have not been diagnosed with CLL/SLL may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment outcomes and quality of life for patients with CLL/SLL.
How similar studies have performed: Previous research has shown promising results with combination therapies in similar contexts, indicating potential for success in this approach.
Where this research is happening
Kansas City, United States
- Kansas City VA Medical Center — Kansas City, United States (Active)
Researchers
- Principal investigator: Kambhampati, Suman — Kansas City VA Medical Center
- Study coordinator: Kambhampati, Suman
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.